Clinical features and outcomes of patients with synchronous cancers in West Virginia.

T Tyler Drummond (West Virginia University School of Medicine, Department of Medical Oncology, Morgantown, WV) Y Yashan Thakkar (Indiana University, Indianapolis, IN) S Sijin Wen J John Moise (West Virginia University School of Medicine, Department of Medical Oncology, Morgantown, WV) A Andrew Gordon (West Virginia University School of Medicine, Department of Medical Oncology, Morgantown, WV) L Lindsay Wilson J Jeevan Murthy (West Virginia University School of Medicine, Department of Medical Oncology, Morgantown, WV) N Nolan Holley (1West Virginia University School of Medicine, Internal Medicine, Morgantown, United States) J Jenna Sizemore (West Virginia University School of Medicine, Department of Medicine, Morgantown, WV) S Samantha Hall (West Virginia University School of Medicine, Department of Medical Oncology, Morgantown, WV) C Carl Shultz (2Transplant and Cellular Therapy/Hematologic Malignancies, West Virginia University Department of Medical Oncology, Morgantown, United States) M Maher Kali (West Virginia University School of Medicine, Department of Medical Oncology, Morgantown, WV) B Bhavana Bhatnagar (16Ohio State University Comprehensive Cancer Center, Columbus, United States) A Ashkan Emadi (3West Virginia University Cancer Institute, Department of Medical Oncology, Morgantown, United States)

Abstract

e23287 Background: Synchronous cancers, defined as ≥2 separate malignancies diagnosed in the same individual within 6 months, pose unique clinical challenges including almost universal exclusion from clinical trials. The prevalence of synchronous cancers has increased, ranging from 2% to 17%. The biology and risk factors for these cancers is not well understood and there is a paucity of data on clinical features and outcomes for these patients. Methods: We retrospectively reviewed charts of patients diagnosed with synchronous cancers at the West Virginia University Cancer Institute between 2020 and 2023. Demographic, geographic, and clinical data were collected. Patient geographic data was geocoded and mapped to federally designated Rural-Urban Commuting Area (RUCA) codes, which range from 1 (urban) to 10 (rural). Kaplan-Meier (log-rank) analysis was performed to investigate differences in 1-year progression-free survival (PFS) and overall survival (OS). Results: There were 285 patients in our analysis with a median age of 66 years (range, 24-98). Most patients had same-system diagnoses with the most common being breast (20.7%), skin (9.1%), lung (8.8%), thyroid (7.4%), and gastrointestinal (GI) (5.6%). The median OS and median PFS were not reached in the current follow-up period. There were significant differences in 1-year PFS (0.42 vs 0.58, P = 0.001) and 1-year OS (0.63 vs 0.79, P < 0.005) between males and females, respectively, and between diagnosis groups (1-year PFS, P < 0.001 and 1-year OS, P = 0.004), with improved survival in breast, thyroid, and skin synchronous cancer patients. Conclusions: To our knowledge, this is the first and largest analysis of rural synchronous cancer patients. Notable survival disparities were observed between males and females and different diagnosis groups. These data are particularly valuable for risk factor assessment in a patient population that is underrepresented in the literature and highlights the need for continuing research.

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (14)

T

Tyler Drummond

West Virginia University School of Medicine, Department of Medical Oncology, Morgantown, WV

Y

Yashan Thakkar

Indiana University, Indianapolis, IN

S

Sijin Wen

J

John Moise

West Virginia University School of Medicine, Department of Medical Oncology, Morgantown, WV

A

Andrew Gordon

West Virginia University School of Medicine, Department of Medical Oncology, Morgantown, WV

L

Lindsay Wilson

J

Jeevan Murthy

West Virginia University School of Medicine, Department of Medical Oncology, Morgantown, WV

N

Nolan Holley

1West Virginia University School of Medicine, Internal Medicine, Morgantown, United States

J

Jenna Sizemore

West Virginia University School of Medicine, Department of Medicine, Morgantown, WV

S

Samantha Hall

West Virginia University School of Medicine, Department of Medical Oncology, Morgantown, WV

C

Carl Shultz

2Transplant and Cellular Therapy/Hematologic Malignancies, West Virginia University Department of Medical Oncology, Morgantown, United States

M

Maher Kali

West Virginia University School of Medicine, Department of Medical Oncology, Morgantown, WV

B

Bhavana Bhatnagar

16Ohio State University Comprehensive Cancer Center, Columbus, United States

A

Ashkan Emadi

3West Virginia University Cancer Institute, Department of Medical Oncology, Morgantown, United States